881202-45-5
881202-45-5
Chemical Structure
Serdemetan
Synonym(s): JNJ-26854165
- CAS No.: 881202-45-5
- Formula:C21H20N4
- Molecular Weight:328.41
IUPAC Name: N1-(2-(1H-indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine
InChIKey: CEGSUKYESLWKJP-UHFFFAOYSA-N
SMILES: C1(NCCC2=CNC3=C2C=CC=C3)=CC=C(C=C1)NC4=CC=NC=C4
Biological Activity: Serdemetan (JNJ-26854165) is a potent anticancer agent with radiosensitizing activity. Serdemetan exhibits antiproliferative activity in various p53 wild-type tumor cells. Serdemetan also antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Serdemetan | 99.56% | Serdemetan (JNJ-26854165) is a potent anticancer agent with radiosensitizing activity. Serdemetan exhibits antiproliferative activity in various p53 wild-type tumor cells. Serdemetan also antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.62
HY-W278232Urease-IN-6 -
Similarity Score 0.60
HY-183698CDK9-IN-51 -
Similarity Score 0.60
HY-1478105-HT7 receptor ligand 1 -
Similarity Score 0.59
HY-155725Z26395438 -
Similarity Score 0.58
HY-137394Nicotredole -
Similarity Score 0.57
HY-D02914-(9H-Carbazol-3-ylamino)phenol -
Similarity Score 0.57
HY-123962G6PD activator AG1 -
Similarity Score 0.56
HY-W856328N-(4-(Pyridin-4-ylamino)phenyl)-4-(quinolin-4-ylamino)benzamide -
Similarity Score 0.56
HY-W725526N-Hydroxyl-tryptamine -
Explore the MedChemAI to find more analogs
References
- [1]. Chargari C, et, al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011 Dec 22;312(2):209-18. [Content Brief]
- [2]. Lehman JA, et, al. Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741. [Content Brief]
- [3]. Jones RJ, et, al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92. [Content Brief]
